The aim of this study is, therefore, to investigate the possible differences in CSF concentrations of GDF15 in AD patients with different degrees of disease severity, as well as its protein expression (both the precursor and the mature form, pro-GDF15 and m-GDF15 respectively) in different brain areas obtained from autoptic samples from subjects of different age (range 33–104 years) with or without AD. Here, GDF15 is linked to Alzheimer disease.